Clinical studies evaluating the efficacy of HDACis in PDAC_
| Drug type | Combination | Comparison | Study phase | Cancer type | Results | Reference |
|---|---|---|---|---|---|---|
| Azacitidine (DNA methyl-transferase inhibitor-DMNTi) and/or romidepsin (HDACi) | nab-Paclitaxel/gemcitabine | - | I (a) | Advanced PDAC | Not available | NCT04257448 |
| Ivaltinostat iv (HDACi) | Capecitabine | Capecitabine monotherapy | I/II | Metastatic PDAC | Not available | NCT05249101 |
| Belinostat iv (HDACi) | Carboplatin Paclitaxel | - | I (c) | Solid tumors | PDAC: 3 pts: PR n = 1 | 92 |
| Tacedinaline po (HDACi) | Gemcitabine | Gemcitabine (1:1) | II (c) | PDAC (unresectable/metastatic) | 174 pts: ORR 12% versus 14%, OS HR 0.98, median OS 6.5 not available versus 7.1 months | NCT00004861 |
| Vorinostat po (HDACi) | Capecitabine Radiotherapy | - | I (c) | Non-metastatic PDAC | 21 pts: median OS 13.2 months | NCT00983268 |
| Vorinostat po (HDACi) | Marizomib | - | I (c) | PDAC NSCLC Melanoma | PDAC: 2 pts | NCT00667082 |
| Panobinostat po (HDACi) | Bortezomib | - | II (c) | Metastatic PDAC | 7 pts: PD n = 7, median PFS 0.86 not available, median OS 4.01 months | NCT01056601 |
| Vorinostat po (HDACi) | Bortezomib | - | I (c) | Solid tumors | PDAC: 6 pts | NCT00227513 |
| Valproic acid po (HDACi) | S-1 | - | I/II (c) | PDAC (unresectable/metastatic) biliary tract cancer (BTC) - Radiation | PDAC: 7 pts | |
| Mocetinostat po (HDACi) | Gemcitabine | - | I/II (c) | Solid tumors | PDAC: 13 pts (Ph II): SD n = 9, median PFS 5.3 not available, median OS 7.4 months | NCT00372437 |
| Resminostat po (HDACi) | S-1 | - | I (c) | PDAC (non-resectable/metastatic) BTC | PDAC: 7 pts; 3 pts (regimen 3): SD n = 2, median PFS 2.3 months, OS 4.7 months | 93 |
| Vorinostat | Radiation therapy-XRT and 5-fluoruracil-5-FU | - | I/II | Advanced PDAC | PDAC: 10 pts; median PFS 9.3 months | NCT00948688 |
| Vorinostat po (HDACi) | Gemcitabine Sorafenib Radiotherapy | - | I (a) | PDAC (resectable, marginally resectable, unresectable) | 22 pts | NCT02349867 |
| Romidepsin iv (HDACi) | Gemcitabine | - | I (c) | PDAC (unresectable/metastatic) Others solid tumors | 14 pts; SD n = 9, PD n = 3; 85% ≥G3 AE | NCT00379639 |
| Romidepsin iv (HDACi) | - | - | I (a) | Solid tumors/lymphomas | PDAC/BTC: 5 pts | NCT01638533 |
| MS-275 (HDACi) | - | - | I (c) | Solid tumors/lymphomas | Not available | NCT00020579 |
| Entinostat po | GSK525762C | - | I | Resistant solid tumors/lymphomas | Not available | NCT03925428 |
| Entinostat po | ZEN003694 | - | I/II | Resistant solid tumors/lymphomas | Not available | NCT05053971 |
| Entinostat po | FOLFOX | - | I | PDAC | Not available | NCT03760614 |
| Entinostat po (HDACi) | Nivolumab | - | II (c) | PDAC (non-resectable/metastatic) BTC | PDAC: 18 pts: CR/PR n = 3, median OS 3.9 months; 63% ≥G3 AE | NCT03250273 |
| Isotretinoin po | Belinostat (HDACi) | - | I (c) | Solid tumors | PDAC: 3 pts: CR/PR/SD n = 0 | NCT00334789 |
| SMMART-prime treatment | - | - | I (a) | Breast cancer (IV), lymphomas, advanced/metastatic/unresectable PDAC, prostate cancer | Not available | NCT03878524 |